September 23, 2019 Clinical Research/Diagn. PR/Corporate

Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress

Basel, 23 September 2019 Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medicine’s FoundationOne® Liquid biopsy assay... Read more

September 20, 2019 Acad, Gov/Utilities

FDA approves cobas Babesia, Roche’s first whole blood test for donor screening

Basel, 20 September 2019 FDA approves cobas Babesia, Roche’s first whole blood test for donor screening Roche is dedicated to helping save patients’ lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infection can be fatal in patients receiving blood transfusions from infected... Read more

September 19, 2019 PR/Corporate

Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary

Basel, 19 September 2019 Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary Roche and Transnet, the main freight logistics company in South Africa, came together in 1994 to establish Phelophepa, the world’s first comprehensive primary healthcare facility on rail Phelophepa has touched the lives of over 14 million people... Read more

September 18, 2019 Acad, Gov/Utilities

FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis

Basel, 18 September 2019 FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal... Read more

September 16, 2019 PR/Corporate

Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running

Basel, 16 September 2019 Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running Roche ranked second in the 2019 Dow Jones Sustainability Indices The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Compared to 2018 Roche significantly... Read more

September 16, 2019 Acad, Gov/Utilities PR/Corporate

Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients

Basel, 16 September 2019 Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients cobas pro integrated solutions improves productivity in the lab and enhances reliability and turnaround times in delivering results to patients By simplifying operations in the lab, Roche is in-turn helping physicians provide evidence-based... Read more

September 13, 2019 Licensing, IP, and Legal PR/Corporate Product Launch

Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis

Basel, 13 September 2019 Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment... Read more

September 13, 2019 PR/Corporate

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer

Basel, 13 September 2019 Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, including the... Read more

September 12, 2019 Bio/Pharma/CRO

Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum

Basel, 12 September 2019 Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 2019 74% reduction in the risk of relapse for satralizumab monotherapy versus placebo... Read more

September 12, 2019 Bio/Pharma/CRO

Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

Basel, 12 September 2019 Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive data... Read more